Review
Molecular medicine: a primer for clinicians. Part IV: Cystic fibrosis and the power and limitations of molecular medicine
Affiliations
- PMID: 7505951
Item in Clipboard
Review
Molecular medicine: a primer for clinicians. Part IV: Cystic fibrosis and the power and limitations of molecular medicine
S D J Med.
1993 Nov.
Abstract
Cystic fibrosis (CF) is among the most common genetic diseases in caucasians of Northern European ancestry. The cloning of the gene responsible for cystic fibrosis, the characterization of the product of the gene and identification of mutations occurring in CF patients are excellent examples of the potential clinical utility of molecular medicine. The ethical issues associated with the ability to identify carriers of CF mutations highlight the magnitude of the questions molecular medicine raises.
Similar articles
-
The molecular biology of cystic fibrosis.Annu Rev Med. 1993;44:133-44. doi: 10.1146/annurev.me.44.020193.001025. Annu Rev Med. 1993. PMID: 7682803 Review.
-
[The cystic fibrosis gene, its product CFTR protein and its mutations].Bull Acad Natl Med. 1993 Mar;177(3):371-80; discussion 380-1. Bull Acad Natl Med. 1993. PMID: 7689915 Review. French.
-
[Molecular basis of cystic fibrosis].Postepy Biochem. 1991;37(3-4):153-8. Postepy Biochem. 1991. PMID: 1725923 Review. Polish. No abstract available.
-
[The cystic fibrosis gene: mutation and the function of CFTR protein].Ann Pediatr (Paris). 1991 Nov;38(9):591-4. Ann Pediatr (Paris). 1991. PMID: 1721508 Review. French.
-
Severe deficiency of cystic fibrosis transmembrane conductance regulator messenger RNA carrying nonsense mutations R553X and W1316X in respiratory epithelial cells of patients with cystic fibrosis.J Clin Invest. 1991 Dec;88(6):1880-5. doi: 10.1172/JCI115510. J Clin Invest. 1991. PMID: 1721624 Free PMC article.